Sponsor
Brittany Pettersen
Representative · D-CO
Representative · D-CO
The resolution defends access to an FDA‑approved medication and prioritizes evidence‑based regulation and existing clean‑water enforcement resources, but it may provoke federal‑state tension and stops short of providing new funding or regulatory remedies for broader water pollution concerns.
Women seeking medication abortion: retain access to the FDA‑reviewed medication mifepristone because the resolution's findings counter efforts to mandate unfounded testing or restrict its use.
State and local governments and the public: enforcement resources for clean‑water priorities are protected by discouraging diversion of testing and funds toward unsubstantiated mifepristone water‑testing, helping preserve attention on known pollutants (e.g., agricultural and industrial waste).
Federal regulators (including the FDA) and the public: the resolution bolsters evidence‑based federal regulatory practice by citing FDA analyses and opposing politically motivated testing mandates that lack scientific support.
State governments and some taxpayers: may view the resolution as federal intrusion into state policymaking because it declares political opposition to certain state actions.
State, local, and federal agencies: the resolution's framing may heighten partisan debate and reduce cooperation between levels of government on contested water‑policy issues.
Local and state governments and communities seeking stronger environmental action: the resolution does not provide new funding or regulatory changes to tackle other water pollution sources, so it may be insufficient for those demanding concrete follow‑up measures.
Based on analysis of 1 section of legislative text.
Finds that science shows mifepristone is safe and concludes proposed water-system monitoring for it is unjustified and would misdirect environmental resources.
Official title: Expressing the sense of the House of Representatives that the monitoring and regulation of water systems not be weaponized for the purposes of surveilling, tracking, or detecting use of, stigmatizing, and further restricting access to medication abortion care.
Introduced June 24, 2026 by Brittany Pettersen · Last progress June 24, 2026
Expresses that scientific evidence and FDA reviews show mifepristone is safe and its residues do not pose environmental risks, and asserts that proposals to monitor or test water systems for the drug are scientifically unjustified. Warns that such monitoring would divert scarce environmental and water-quality resources away from real pollution threats and criticizes state and federal efforts that promote unscientific claims to restrict medication abortion access.